Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

LGBTQ+

- PMLiVE

MHRA authorises world-first gene therapy for two inherited blood disorders

Casgevy is now the first licensed treatment that uses the gene-editing tool CRISPR

- PMLiVE

How to maintain employee engagement for those working remotely

By Jayne Carey-George and Vic Harvey

COUCH Health publishes report to encourage patient engagement in the MedTech sector

Manchester, UK, 27 February 2023 — COUCH Health today announced the publication of a new report “The Power of Patient Engagement in MedTech”.

COUCH Health

- PMLiVE

Novartis gains global rights to Legend’s CAR-T cell therapies in deal worth over $1bn

Novartis can apply its T-Charge platform to the manufacturing process of the therapies

- PMLiVE

New genetic variants linked to prostate cancer in men with African ancestry

A dataset was compiled for the research containing DNA from over 944,000 men

- PMLiVE

AstraZeneca shares positive phase 3 results for Imfinzi combination in liver cancer

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

- PMLiVE

Maintaining employee engagement while working remotely

By Tony Woods

EU Joint Clinical Assessment (JCA) – implications for Pharma and Medtech

Maria Dimitrova (Consultant – HTA) and Samantha Gillard (Director – HTA) provide an overview of the EU Joint Clinical Assessment (JCA) and what it means for Pharma and Medical Device...

Petauri Evidence

- PMLiVE

Market access and reimbursement in key European markets

An introductory guide to European market access and reimbursement stakeholders and processes in France, Great Britain, Germany, Italy and Spain.

Petauri Evidence

- PMLiVE

Almirall and Absci announce $650m AI dermatological drug discovery partnership

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology

- PMLiVE

Roche’s subcutaneous Tecentriq recommended by CHMP for multiple cancer types

The formulation can cut treatment time by approximately 80% compared to intravenous infusion

- PMLiVE

New WHO initiative to prioritise endemic pathogens for vaccine development

Value profiles of 16 pathogens with vaccines in clinical development will be featured

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links